Vaccine Therapy in Treating Patients With Malignant Glioma

Eligibility Criteria: * Histologically confirmed diagnosis of one of the following malignant gliomas: * Anaplastic astrocytoma * Glioblastoma multiforme * Anaplastic oligodendroglioma * Malignant mixed oligoastrocytoma * WHO grade III or IV disease * Newly diagnosed disease * Bidimensionally measurable disease by contrast-enhancing MRI * Surgically accessible tumor for which resection is indicated * Previously treated with or plan to undergo treatment with conventional external beam radiotherapy * Age 18 and over * Performance status Karnofsky 60-100% * Life expectancy at least 8 weeks * Hemoglobin at least 10 g/dL * Absolute granulocyte count at least 1,500/mm\^3 * Platelet count at least 100,000/mm\^3 * SGOT and SGPT no greater than 2 times normal * Alkaline phosphatase no greater than 2 times normal * Bilirubin no greater than 1.5 mg/dL * Hepatitis B negative * Hepatitis C negative * BUN no greater than 1.5 times normal * Creatinine no greater than 1.5 times normal * HIV negative * Syphilis serology negative * Afebrile * Negative pregnancy test * Fertile patients must use effective contraception * At least 2 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered. * At least 2 weeks since prior corticosteroids * At least 2 weeks since prior radiotherapy and recovered * More than 72 hours since prior systemic antibiotics Exclusion Criteria: * active infection * immunodeficiency * autoimmune disease that may be exacerbated by immunotherapy, including any of the following: * Rheumatoid arthritis * Systemic lupus erythematosus * Vasculitis * Polymyositis-dermatomyositis * Scleroderma * Multiple sclerosis * Juvenile-onset insulin-dependent diabetes * allergy to study agents * pregnant or nursing * underlying condition that would contraindicate study therapy * concurrent severe or unstable medical condition that would preclude giving informed consent * psychiatric condition that would preclude study participation or giving informed consent * other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, localized prostate cancer, or carcinoma in situ of the cervix * concurrent chemotherapy during and for 2 weeks after administration of study vaccine * concurrent corticosteroids prior organ allograft * antihistamine therapy within 5 days before or after administration of study vaccine * other concurrent investigational agents * concurrent adjuvant therapy during and for 2 weeks after administration of study vaccine